Analyst firms · William Blair · JSPR
William Blair JSPR price target and rating history
Jasper Therapeutics Inc. (JSPR) · Health Care
William Blair rates Jasper Therapeutics Inc. (JSPR) Outperform, as of its latest action on Oct 14, 2026. It has published 3 rating actions on JSPR since October 2021, including 0 upgrades and 1 downgrade. Across 3 firms with a JSPR price target in the last 12 months, the median target is $2.
- Current rating
- Outperform
- Price target
- Not stated
- Median target, all firms
- $2
- Actions on JSPR
- 3
Every William Blair rating on JSPR
- Oct 14, 2026
- Jul 7, 2025
- Oct 21, 2021
How other firms rate JSPR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| William Blair | Outperform | Oct 14, 2026 | |
| Piper Sandler | Overweight | $2 | Aug 12, 2026 |
| TD Cowen | Hold | May 15, 2026 | |
| UBS | Neutral | $1.50 | Mar 23, 2026 |
| Rodman & Renshaw | Buy | $17 | Jan 13, 2026 |
Questions about William Blair and JSPR
- What is William Blair's rating on JSPR?
- William Blair rates JSPR Outperform, a bullish rating, as of Oct 14, 2026.
- When did William Blair last change its view on JSPR?
- On Oct 14, 2026, William Blair resumes coverage at Outperform.
- How does William Blair's JSPR target compare with other analysts?
- Across 3 firms with a JSPR price target in the last 12 months, the median target is $2.
More JSPR rating histories
All William Blair ratingsJSPR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.